Clinical Trials Sponsored by LEGO

Total 338 results

1
2
3
4
5
6
7
›

University of Copenhagen
LEGO Foundation

Recruiting

The Playful Learning in Infancy Program (PLIP)

Parent-Child Relations | Infant Development

Denmark
Tego Science, Inc.

Recruiting

A Phase 2b/3 Study of TPX-115 on Partial-thickness Rotator Cuff Tear

Partial Thickness Rotator Cuff Tear

Korea, Republic of
Tego Science, Inc.

Completed

Safety and Efficacy Study of TPX-105 for Correction of Nasojugal Groove

Tear Trough Eyelid Deformity

Korea, Republic of
Tego Science, Inc.

Completed

A Phase I/III Clinical Study of TPX-114 for the Treatment of Full-Thickness Rotator Cuff Tear

Rotator Cuff Injuries

Korea, Republic of
Levo Therapeutics, Inc.

Completed

Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome (CARE-PWS)

Prader-Willi Syndrome

United States, Canada, Australia
Mego Afek Ltd.

Completed

Safety and Efficacy Study of a New Intermittent Pneumatic Compression Device to Treat Patients With Peripheral Arterial Disease (PAD) Stage II

Peripheral Arterial Disease

Israel, Germany
Tego Science, Inc.

Recruiting

Safety Study of TPX-121 on Nasolabial Folds

Nasolabial Fold, Hypoplastic

Korea, Republic of
Tego Science, Inc.

Completed

Phase 1/2 Clinical Study of TPX-115 in Patients With Partial-Thickness Rotator Cuff Tear

Rotator Cuff Injuries

Korea, Republic of
LEO Pharma

Not yet recruiting

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

Palmoplantar Pustulosis
LEO Pharma

Completed

A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema (DELTA FORCE)

Chronic Hand Eczema

France, Germany, Italy, Poland, Spain, United Kingdom, Austria, Canada, Norway, Slovakia
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds

Psoriasis Vulgaris

United Kingdom, France, Canada
LEO Pharma

Completed

LEO19123 Cream in the Treatment of Hand Eczema

Hand Eczema

United Kingdom
LEO Pharma

Completed

Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects

Psoriasis Vulgaris

Japan
LEO Pharma

Active, not recruiting

Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)

Atopic Dermatitis

Spain, United Kingdom, Czechia, France, Netherlands
LEO Pharma

Terminated

A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp

Actinic Keratosis | Squamous Cell Carcinoma

United States, Spain, Canada, Germany, France, United Kingdom
LEO Pharma

Completed

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) (ECZTRA 1)

Atopic Dermatitis

United States, Japan, France, Germany, Spain
LEO Pharma

Completed

A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin

Skin and Connective Tissue Diseases

Germany
LEO Pharma

Completed

A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas

Psoriasis Vulgaris

France
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis (EMBRACE 1)

Psoriasis

Belgium, Germany, Italy, Poland, Spain, France, Greece, Hungary
LEO Pharma

Completed

Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis

Scalp Psoriasis

China
LEO Pharma

Completed

A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin

Connective Tissue Diseases | Skin Tissue Diseases

Germany
LEO Pharma

Completed

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Actinic Keratosis

United States
LEO Pharma

Completed

Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest

Actinic Keratosis

United States
LEO Pharma

Completed

A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis

Psoriasis Vulgaris

Germany
LEO Pharma

Terminated

Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma

Liver Neoplasms

Spain, Canada, France, Italy, United Kingdom
LEO Pharma

Completed

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
LEO Pharma

Completed

A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

Germany
LEO Pharma

Completed

A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

France
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis

Psoriasis of Scalp

Canada, Belgium, Finland, France, Germany, Netherlands, United Kingdom
LEO Pharma

Terminated

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

Discoid Lupus Erythematosus

United States, France, Germany, Denmark
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Actinic Keratosis

Germany
LEO Pharma

Completed

Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream

Atopic Dermatitis

United Kingdom
LEO Pharma

Completed

LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

France
LEO Pharma

Completed

A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris

Psoriasis Vulgaris

France
LEO Pharma

Completed

A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD

Atopic Dermatitis

Austria
LEO Pharma

Completed

A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

Canada, France
LEO Pharma

Completed

Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Scalp Psoriasis

Canada, United Kingdom, France
LEO Pharma

Completed

LEO 90100 in the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

United States
LEO Pharma

Completed

Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp

Actinic Keratosis

Canada, Germany, Australia, France, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis

Psoriasis of Scalp

Canada, Denmark, France, Germany, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Actinic Keratosis

United States
LEO Pharma

Completed

Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
LEO Pharma

Completed

An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris

Psoriasis Vulgaris

France
LEO Pharma

Completed

Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

Actinic Keratosis

United States
LEO Pharma

Completed

An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A

Psoriasis Vulgaris

Denmark
LEO Pharma

Completed

Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)

Psoriasis Vulgaris

United States
LEO Pharma

Completed

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

Atopic Dermatitis

United States, Germany, Belgium, Canada, Spain, United Kingdom, Poland, Netherlands
LEO Pharma

Completed

Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis

Psoriasis Vulgaris

United States, Netherlands, Poland, Romania
LEO Pharma

Completed

A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

Actinic Keratosis

United States

1
2
3
4
5
6
7
›

3

Subscribe